Coeptis Therapeutics Holdings Inc. COEP 深 沪

Coeptis net loss narrows to $4.02 million in Q1 FY26; revenue rises 80.93% to $113,771

Coeptis net loss narrows to $4.02 million in Q1 FY26; revenue rises 80.93% to $113,771 Coeptis Therapeutics Holdings posted a net loss of USD 4.02 million for the three months ended March 31, 2026, while revenue rose 80.92% to USD 113,771. Operating expenses edged down 2.24% to USD 3.98 million, whi

05-15 18:31

Coeptis Therapeutics Advances Business Combination, Nasdaq Listing Plans

The latest announcement is out from Coeptis Therapeutics Holdings ( ($COEP) ). ...

04-28 21:35

Z Squared Provides Additional Information on Previously Disclosed Pro Rata Distribution

FORT LAUDERDALE, Fla., April 27, 2026 /PRNewswire/ -- Z Squared, Inc. (NASDAQ: ZSQR) ("Company") today issued supplemental information related to its previously announced business combinatio...

04-27 23:31

Coeptis Therapeutics Announces Nasdaq Grants Approval For Post-Merger Listing Under 'ZSQR' Ticker; Coeptis-Z Squared Merger Expected To Close Q2 2026

The transaction remains subject to satisfaction of any remaining customary closing conditions, and there can be no assurance that such conditions will be satisfied.

04-08 00:08

Coeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing Application

04-07 16:05

Coeptis Reprices Equity Awards and Accelerates Option Vesting

Coeptis Therapeutics Holdings ( ($COEP) ) has shared an update. On February 11,...

02-13 06:34

Coeptis Shareholders Approve Merger, Spin-Out and Rebranding

Coeptis Therapeutics Holdings ( ($COEP) ) has provided an announcement. At an A...

02-05 06:13

Coeptis Therapeutics Addresses Nasdaq Listing Compliance Deficiency

Coeptis Therapeutics Holdings ( ($COEP) ) just unveiled an update. On January 1...

01-17 06:03

Coeptis Therapeutics' SEC-Approved S-4 Clears Path For Z Squared Merger, Stockholder Vote Set For January 30

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or the "Company"), a next-gen technology and biopharmaceutical company, , announced today that its registration statement on Form S-4 (File No. 333-288329)

01-06 21:23

Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that its registration statement on Form S-4, related to its merger with Z Squared Inc. (ZSQ), has been declared effective by the SEC. The company will hold its Annual/Special Meeting of Shareholders on January 30, 2026, and has begun mailing the definitive proxy statement/prospectus to its shareholders of record as of January 2, 2026. The combined company has applied to list its common ...

01-06 13:19